Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 16/20 | 0.57 |
| ▸ | CYP11B2 | P19099 | 16/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 7/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.57 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.57 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.57 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.43 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.41 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3324853 | 1.00 | CYP11B1 (0.57) | CYP11B1CYP11B2CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL3323501 | 1.00 | CYP11B1 (0.57) | CYP11B1CYP11B2CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL4135895 | 0.87 | CYP11B1 (0.40) | CYP11B1CYP11B2CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL4139788 | 0.86 | CYP11B2 (0.39) | CYP11B1CYP11B2CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL4139793 | 0.86 | CYP11B2 (0.39) | CYP11B1CYP11B2CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL4142343 | 0.86 | HRH3 (0.40) | CYP11B1CYP11B2CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL4129121 | 0.84 | HRH3 (0.39) | CYP11B1CYP11B2CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL4141100 | 0.83 | HRH3 (0.38) | CYP11B1CYP11B2CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL4144375 | 0.82 | CYP11B2 (0.63) | CYP11B1CYP11B2CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL4129139 | 0.82 | CYP11B2 (0.63) | CYP11B1CYP11B2CYP1A2CYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090163482-A1 | TETRALINES ANTAGONISTS OF THE H-3 RECEPTOR | MCHARDY STANTON FURST | 2009-06-25 | — | — | US | claimed |
| US-20150011759-A1 | PROCESSES FOR PREPARING (R)-2-METHYLPYRROLIDINE AND (S)-2-METHYLPYRROLIDINE AND TARTRATE SALTS THEREOF | CEPHALON, INC. (US) | 2015-01-08 | — | — | US | disclosed |
| US-20100121055-A1 | PROCESSES FOR PREPARING (R)-2-METHYLPYRROLIDINE AND (S)-2-METHYLPYRROLIDINE AND TARTRATE SALTS THEREOF | CEPHALON, INC. (US) | 2010-05-13 | — | — | US | disclosed |
| US-20090163482-A1 | TETRALINES ANTAGONISTS OF THE H-3 RECEPTOR | MCHARDY STANTON FURST | 2009-06-25 | — | — | US | disclosed |
| EP-2007749-A2 | TETRALINES ANTAGONISTS OF THE H-3 RECEPTOR | Pfizer Products Inc. (US) | 2008-12-31 | — | — | EP | disclosed |
| WO-2007105053-A2 | TETRALINES ANTAGONISTS OF THE H-3 RECEPTOR | PFIZER PRODUCTS INC. (US) | 2007-09-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150011759-A1 | PROCESSES FOR PREPARING (R)-2-METHYLPYRROLIDINE AND (S)-2-METHYLPYRROLIDINE AND TARTRATE SALTS THEREOF | TPMT, SPR, QDPR | CYP11B1 1271/4885CYP11B2 638/4885CYP1A2 265/4885 |
| US-20090163482-A1 | TETRALINES ANTAGONISTS OF THE H-3 RECEPTOR | HRH3, HRH4, HRH1 | CYP11B1 810/4885CYP11B2 745/4885CYP1A2 1220/4885 |
| US-20100121055-A1 | PROCESSES FOR PREPARING (R)-2-METHYLPYRROLIDINE AND (S)-2-METHYLPYRROLIDINE AND TARTRATE SALTS THEREOF | TPMT, SPR, QDPR | CYP11B1 1271/4885CYP11B2 638/4885CYP1A2 265/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.